Literature DB >> 29491762

Emerging Therapeutic Targets for Hepatitis Delta Virus Infection.

Jeffrey S Glenn1.   

Abstract

Entities:  

Year:  2018        PMID： 29491762      PMCID： PMC5824596     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  6 in total

Review 1.  Hepatitis delta infection - Current and new treatment options.

Authors:  Menashe Elazar; Christopher Koh; Jeffrey S Glenn
Journal:  Best Pract Res Clin Gastroenterol       Date:  2017-05-22       Impact factor: 3.043

Review 2.  Emerging concepts for the treatment of hepatitis delta.

Authors:  Menashe Elazar; Jeffrey S Glenn
Journal:  Curr Opin Virol       Date:  2017-05-02       Impact factor: 7.090

3.  Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.

Authors:  Christopher Koh; Laetitia Canini; Harel Dahari; Xiongce Zhao; Susan L Uprichard; Vanessa Haynes-Williams; Mark A Winters; Gitanjali Subramanya; Stewart L Cooper; Peter Pinto; Erin F Wolff; Rachel Bishop; Ma Ai Thanda Han; Scott J Cotler; David E Kleiner; Onur Keskin; Ramazan Idilman; Cihan Yurdaydin; Jeffrey S Glenn; Theo Heller
Journal:  Lancet Infect Dis       Date:  2015-07-16       Impact factor: 25.071

4.  Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.

Authors:  Pavel Bogomolov; Alexander Alexandrov; Natalia Voronkova; Maria Macievich; Ksenia Kokina; Maria Petrachenkova; Thorsten Lehr; Florian A Lempp; Heiner Wedemeyer; Mathias Haag; Matthias Schwab; Walter E Haefeli; Antje Blank; Stephan Urban
Journal:  J Hepatol       Date:  2016-04-27       Impact factor: 25.083

5.  Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.

Authors:  Cihan Yurdaydin; Onur Keskin; Çağdaş Kalkan; Fatih Karakaya; Aysun Çalişkan; Ersin Karatayli; Senem Karatayli; A Mithat Bozdayi; Christopher Koh; Theo Heller; Ramazan Idilman; Jeffrey S Glenn
Journal:  Hepatology       Date:  2018-02-19       Impact factor: 17.425

6.  Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.

Authors:  Michel Bazinet; Victor Pântea; Valentin Cebotarescu; Lilia Cojuhari; Pavlina Jimbei; Jeffrey Albrecht; Peter Schmid; Frédéric Le Gal; Emmanuel Gordien; Adalbert Krawczyk; Hrvoje Mijočević; Hadi Karimzadeh; Michael Roggendorf; Andrew Vaillant
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-09-28
  6 in total
  1 in total

1.  Hepatitis D infection: from initial discovery to current investigational therapies.

Authors:  Ben L Da; Theo Heller; Christopher Koh
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-06-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.